Novartis' BAF312 meets main goal in secondary progressive multiple sclerosis trial - Pharmaceutical Business Review

Pharmaceutical Business Review

Novartis' BAF312 meets main goal in secondary progressive multiple sclerosis trial Pharmaceutical Business Review A phase III study, assessing the efficacy and safety of Novartis' BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS), met its primary endpoint of a reduction in the risk of disability progression, versus placebo. Novartis claims that ... Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MSNasdaq all 3 news articles »

Novartis' BAF312 meets main goal in secondary progressive multiple sclerosis trial - Pharmaceutical Business Review
Read More